Amarin Corporation plc (NASDAQ:AMRN) will present new REDUCE-IT and EPA analyses at the European Society of Cardiology Congress 2026, adding further research around icosapent ethyl, cardiovascular risk factors and potential mechanisms associated with eicosapentaenoic acid.
The presentations, scheduled for August 28 through August 30 during the Munich conference, will examine areas including treatment adherence, longer-term outcomes, lipoprotein(a), coagulation biomarkers and cellular pathways relevant to cardiovascular disease.
Amarin is bringing several new analyses from its cardiovascular research programme to one of Europe’s major cardiology meetings, with presentations beginning August 28.
One moderated poster will examine adherence and potential longer-term “legacy effects” associated with high-dose EPA in patients with hypertriglyceridemia and high cardiovascular risk from REDUCE-IT.
Another REDUCE-IT analysis will investigate differences between men and women in early study discontinuation and study drug withdrawal.
On August 30, researchers will present a post hoc analysis examining the effects of icosapent ethyl on coagulation biomarkers and their relationship with event-free survival in high-risk cardiovascular patients.
A separate mechanistic presentation will explore the effect of EPA on rapid oxidation of lipoprotein(a), or Lp(a), and resulting changes in endothelial cell protein expression that researchers suggest may contribute to clinical benefits.
An oral presentation will also examine Lp(a) variability among high cardiovascular-risk patients with hypertriglyceridemia and controlled LDL cholesterol while receiving statin therapy.
The ESC presentations could help deepen the scientific narrative around Amarin’s cardiovascular franchise by examining questions that extend beyond the principal findings of REDUCE-IT.
In particular, analyses involving longer-term outcomes, biomarkers and possible biological mechanisms may provide additional context around how EPA and icosapent ethyl interact with cardiovascular risk.
The Lp(a) research may also broaden the discussion around cardiovascular risk factors within the REDUCE-IT population, while the coagulation analysis could provide additional insight into associations between treatment, biomarkers and clinical outcomes.
For investors, however, these are primarily scientific rather than immediate commercial or regulatory catalysts. The announcement provides no new revenue guidance, regulatory decisions or changes to Amarin’s commercial strategy.
Their importance will therefore depend on the findings presented at ESC and whether those results add meaningful evidence to the existing clinical and mechanistic case surrounding icosapent ethyl and EPA.
The first presentations are scheduled for August 28, including the REDUCE-IT legacy analysis, sex-difference research and the oral presentation covering Lp(a) variability.
Attention then shifts to August 30, when researchers will present the coagulation biomarker analysis and mechanistic research involving EPA and Lp(a) oxidation.
The actual findings from these presentations, particularly any new evidence regarding long-term outcomes or mechanisms associated with cardiovascular effects, will determine their significance for Amarin’s broader scientific positioning.
Amarin Corporation stock price
| 1 hour | |
| 3 hours | |
| Jul-29 | |
| Jul-29 | |
| Jul-29 | |
| Jul-29 | |
| Jul-15 | |
| Jun-30 | |
| Jun-05 | |
| May-27 | |
| May-27 | |
| Apr-30 | |
| Apr-29 | |
| Apr-29 | |
| Apr-29 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite